Cervical Intraepithelial Neoplasia (CIN) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
All the vital news, analysis, and commentary curated by our industry experts.
Cervical Intraepithelial Neoplasia Pipeline Drugs Market Overview
Cervical Intraepithelial Neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge, and low back pain.
The CIN pipeline drugs market research report provides comprehensive information on the therapeutics under development for CIN, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for CIN and features dormant and discontinued projects.
CIN Pipeline Drugs Market Segmentation by Targets
The key targets in the CIN pipeline drugs market are Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, DNA Polymerase, Human Papillomavirus Minor Capsid Protein L2, and others. Human Papillomavirus Protein E7 has the highest number of products in development in the CIN pipeline drugs market in 2022.
CIN Pipeline Drugs Market Analysis by Targets
For more target insights into the CIN pipeline drugs market, download a free report sample
CIN Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action in the CIN pipeline drugs market are Human Papillomavirus Protein E7 Inhibitor, Human Papillomavirus Protein E6 Inhibitor, DNA Polymerase Inhibitor, Delta Aminolevulinic Acid Dehydratase Inhibitor, and others. Human Papillomavirus Protein E7 Inhibitor leads the CIN pipeline drugs market in terms of MoA.
CIN Pipeline Drugs Market Analysis by Mechanisms of Action
For more MoA insights into the CIN pipeline drugs market, download a free report sample
CIN Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the CIN pipeline drugs market are intramuscular, vaginal, oral, subcutaneous, and others. The intramuscular RoA has the highest number of CIN drugs in development in 2022.
CIN Pipeline Drugs Market Analysis by RoA
For more RoA insights into the CIN pipeline drugs market, download a free report sample
CIN Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the CIN pipeline drugs market are small molecule, subunit vaccine, recombinant vector vaccine, DNA vaccine, and others. Small molecule leads the CIN pipeline drugs market in terms of molecule type.
CIN Pipeline Drugs Market Analysis by Molecule Types
For more molecule type insights into the CIN drugs market, download a free report sample
CIN Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the CIN pipeline drugs market are Antiva Biosciences Inc, Bioleaders Corp, Genexine Inc, Novan Inc, Papivax LLC, Shanghai Bovax Biotechnology Co Ltd, and others.
CIN Pipeline Drugs Market Analysis by Companies
To know more about the leading CIN pipeline drugs market players, download a free report sample
CIN Pipeline Products Market Overview
|Key Targets||Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, DNA Polymerase, Human Papillomavirus Minor Capsid Protein L2, and Others|
|Key Mechanisms of Action||Human Papillomavirus Protein E7 Inhibitor, Human Papillomavirus Protein E6 Inhibitor, DNA Polymerase Inhibitor, Delta Aminolevulinic Acid Dehydratase Inhibitor, and Others|
|Key Routes of Administration||Intramuscular, Vaginal, Oral, Subcutaneous, and Others|
|Key Molecule Type||Small Molecule, Subunit Vaccine, Recombinant Vector Vaccine, DNA Vaccine, And Others|
|Leading Companies||Antiva Biosciences Inc, Bioleaders Corp, Genexine Inc, Novan Inc, Papivax LLC, Shanghai Bovax Biotechnology Co Ltd, and Others|
- The pipeline guide provides a snapshot of the global therapeutic landscape of CIN.
- The pipeline guide reviews pipeline therapeutics for CIN by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in CIN therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates CIN therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for CIN
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for CIN.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the CIN pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Asieris Pharmaceuticals Co Ltd
Beijing Kangle Guardian Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
Blue Sky Immunotherapies GmbH
Chengdu Institute of Biological Products Co Ltd
Douglas Pharmaceuticals Ltd
Frantz Viral Therapeutics LLC
GenoLac BL Corp
Hefei Ruichengsheng Biotechnology Co Ltd
Inovio Pharmaceuticals Inc
Merck & Co Inc
Nykode Therapeutics ASA
PDS Biotechnology Corp
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) – Overview
Cervical Intraepithelial Neoplasia (CIN) – Therapeutics Development
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) – Companies Involved in Therapeutics Development
Cervical Intraepithelial Neoplasia (CIN) – Drug Profiles
Cervical Intraepithelial Neoplasia (CIN) – Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) – Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) – Product Development Milestones
Featured News & Press Releases
Mar 08, 2022: Nykode Therapeutics to present at 2022 American Association for Cancer Research (AACR) Annual Meeting
Dec 14, 2021: INOVIO highlights key updates on phase 3 program for VGX-3100, its DNA-based immunotherapy for the treatment of cervical HSIL caused by HPV-16 and/or HPV-18
Apr 21, 2021: Antiva Biosciences appoints Clifford Samuel to Board of Directors
Mar 26, 2021: The VGX-3100 project of Dongfanglue passed the approval of the Genetics Office, and officially launched the domestic phase III clinical trial
Feb 20, 2020: Novan receives phase 2 NIH federal grant of approximately $1.0 million
Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event
Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019
Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting
Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data
Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial
Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer
Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene’ TG4001
May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100
Apr 17, 2019: Inovio’s phase 3 HPV immunotherapy selected as “Best Therapeutic Vaccine” at World Vaccine Congress
Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers
Expert Panel Validation
Frequently asked questions
What are the key targets in the CIN pipeline drugs market?
The key targets in the CIN pipeline drugs market are Human Papillomavirus Protein E7 Inhibitor, Human Papillomavirus Protein E6 Inhibitor, DNA Polymerase Inhibitor, Delta Aminolevulinic Acid Dehydratase Inhibitor, and others.
What are the key mechanisms of action in the CIN pipeline drugs market?
The key MoA in the CIN pipeline drugs market are Human Papillomavirus Protein E7 Inhibitor, Human Papillomavirus Protein E6 Inhibitor, DNA Polymerase Inhibitor, Delta Aminolevulinic Acid Dehydratase Inhibitor, and others.
What are the key routes of administration in the CIN pipeline drugs market?
The key RoA in the CIN pipeline drugs market are intramuscular, vaginal, oral, subcutaneous, and others.
What are the key molecule types in the CIN pipeline drugs market?
The key molecule types in the CIN pipeline drugs market are small molecule, subunit vaccine, recombinant vector vaccine, DNA vaccine, and others.
Which are the leading companies in the CIN pipeline drugs market?
Some of the leading companies in the CIN pipeline drugs market Antiva Biosciences Inc, Bioleaders Corp, Genexine Inc, Novan Inc, Papivax LLC, and Shanghai Bovax Biotechnology Co Ltd.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.